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Background
Patients with breast cancer that express estrogen receptor-
alpha (ERα+) are candidates for endocrine therapies. 
Although endocrine therapies are among the most 
successful targeted therapies in oncology, a signiﬁ cant 
subset of ER+ breast cancers have become resistant to 
them. Th e activation of growth factor receptor (GFR) 
pathways has been identiﬁ ed as a possible culprit, and 
although ER is rarely mutated in endocrine-resistant 
tumors, it can be aberrantly activated by GFR signaling in 
a ligand-independent manner [1].
Over the last few years, the application of chromatin 
immunoprecipitation (ChIP) coupled with massively 
parallel sequencing (ChIP-seq) enabled the identiﬁ cation 
of the ER cistrome in breast cancer cells [2]. By showing 
the following, the results brought an end to the dogma 
that ER binds primarily to the proximal promoters: (a) ER 
frequently binds distal enhancers [3], (b)  the forkhead 
protein FoxA1 is necessary for ER-chromatin interactions 
[3-6], and (c) activation of GFR signaling results in the 
redirection of ER binding [7]. However, all previous 
studies, though highly informative, were performed in 
cell lines (primarily MCF-7 cells). Obtaining ChIP-seq 
results from primary breast tumors was the next step that 
everyone was eagerly awaiting.
The article
Ross-Innes and colleagues [8] analyzed ER ChIP-seq data 
from 15 ER+ tumors (eight with a good prognosis and 
seven with a poor prognosis) and three distant meta-
stases. Th e authors found a core set of 484 ER-binding 
events present in at least 75% of all ER+ tumors (but not 
in the ER− controls). Intriguingly, ER-binding signal 
intensity was highest in metastatic samples and lowest in 
patients with good outcomes, suggesting that binding 
intensity may correspond to disease progression. Diﬀ er-
en tial binding analysis found 1,192 ER-binding events 
that were stronger in the poor prognosis/metastasis 
group in comparison with the good outcome samples and 
found 599 binding events more prevalent in the good 
outcome tumors. Motif analysis revealed the presence of 
estrogen response element (ERE) sites in all three groups 
but a unique enrichment of FoxA1 sites in the poor 
prognosis/metastatic tumors. An important ﬁ nding was 
that ER still bound DNA in tumors resistant to hormonal 
therapies but was recruited to novel sites in the genome. 
Th ese sites are functionally and biologically relevant 
since a gene expression predictor based on genes within a 
20-kb window of the binding sites was associated with 
survival in ER+ data sets.
Treatment of breast cancer cells (whose ER cistrome 
closely overlaps with that of poor prognosis/metastatic 
tumors, presumably because the cell lines were isolated 
from metastases) with a mitogenic cocktail also resulted 
in rapid enrichment of novel ER-binding sites. 
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In triguingly, half of these binding sites occurred in 
regions to which FoxA1 was already bound or to which 
FoxA1 was recruited in response to mitogenic stimulus. 
High and correlated expression of ER and FoxA1 in 
metastatic samples further supports the idea that FoxA1 
might direct the reprogramming of ER binding in 
advanced disease.
Viewpoint
Th is study presents an important and exciting milestone 
in our eﬀ orts to understand the plasticity of ER function 
in breast tumors. Although the numbers of samples are 
small, the data strongly suggest that diﬀ erential ER 
binding is associated with the outcome of patients with 
breast cancer. Increasing the number of samples will 
allow the analysis of poor outcome tumors separately 
from metastases, a critical question given the lack of 
knowledge about the role of ER in metastasis.
An interesting ﬁ nding of the study is the observation 
that the average ER-binding signal was highest in the 
metastatic samples. Additional studies are necessary to 
determine whether this is a general phenomenon and, if 
so, the underlying mechanisms. Th is could include altered 
levels or post-translational modiﬁ cation of ER (or both) 
or altered interaction of ER with co-regulator proteins. 
Alternatively, this may be simply a result of increased 
tumor cellularity or decreased tumor cell heterogeneity 
in metastatic samples or both. In any case, this is a 
curious ﬁ nding and deserves further study.
For us, however, the most interesting observation is 
that reprogramming of ER binding seems to be associated 
with co-recruitment of FoxA1 and frequently with 
recruitment to sites pre-bound by FoxA1. Although this 
study does not include FoxA1 ChIP-seq data from clinical 
samples, the in vitro data point toward a unique 
mechanism of FoxA1 binding to ‘pre-marked’ DNA in 
poor outcome tumors, and this may have critical clinical 
relevance. Th e further use of frozen tumor specimens for 
ChIP-seq studies and the use of paraﬃ  n-embedded 
samples as recently described by Fanelli and colleagues 
[9,10] will undoubtedly shed more light on these 
questions.
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